bipolar disorder
Bipolar Disorder Overview
Definition: A lifelong cyclic mood disorder characterized by recurrent episodes of mood and behavioral changes: mania, hypomania, euthymia, or depressive mood.
Clinical Presentation
Chronic Condition: Bipolar disorder is chronic and lifelong, with recurrent mood episodes.
Residual Symptoms: Residual (subsyndromal) symptoms may persist even with treatment.
Prevalence of Symptoms: Depressive symptoms predominate, accounting for approximately $ rac{1}{3}$ of illness duration.
Diagnosis
Initial Steps: First, rule out medications and substance-induced causes, as well as medical or psychiatric conditions.
Manic Episode Criteria
Observable Symptoms: Obvious to everyone around the individual.
Mood Changes: Characterized by abnormally and persistently increased activity or energy, expansive or persistent irritable mood.
Functional Impairment: Can involve quitting a job, hospitalization, or experiencing psychosis.
Key Mania Symptoms: Minimum of three symptoms present:
Grandiosity: Exaggerated achievements, a belief of being special or powerful, rules disregarded, lack of empathy, manifested as arrogance and boasting, difficulty accepting criticism.
Decreased Sleep: Usually the first symptom that presents; the individual feels they don’t need sleep, believing they have significant tasks to accomplish.
Pressured Speech: Rapid speech patterns underpinned by a sense of urgency.
Distractibility: Difficulty focusing, easily sidetracked by irrelevant stimuli.
Increased Goal-Driven Activity or Risky Behavior: Money spending, gambling, or sexual activity.
Duration: Symptoms must persist for greater than one week; duration does not matter if hospitalized.
Hypomanic Episode
Defined as mania without hospitalization, functional impairment, or psychosis.
Duration: Greater than four days.
Major Depressive Episode (MDE)
Criteria: Greater than five symptoms persisting for more than two weeks, with at least one symptom being:
Depressed Mood or Loss of Interest.
Diagnostic Mnemonic: M SIG E CAPS
M: Mood (depressed or irritable)
S: Sleep (insomnia or hypersomnia)
I: Interest (loss of interest in most activities)
G: Guilt (feelings of worthlessness or excessive guilt)
E: Energy (fatigue or loss of energy)
C: Concentration (diminished ability to think or concentrate)
A: Appetite (weight loss or gain unrelated to dieting)
P: Psychomotor Agitation or Retardation (observable by others)
S: Suicidal Ideation
Bipolar Disorder Types
Bipolar 1 Disorder:
Core Distinction: Must have at least one manic episode. Can also include hypomania or MDE.
Typical Presentation: Mania usually presents as the first episode.
Bipolar 2 Disorder:
Characterization: Associated with chronic depression.
Symptom Criteria: Greater than one hypomanic episode and greater than one MDE. No history of manic episodes.
Depressive Burden: Often more chronic with increased time spent in depressive episodes.
Risks: Increased risk of suicide.
Cyclothymic Disorder (for informational purposes):
Characteristics: Chronic fluctuating mood symptoms that never meet the criteria for hypomania or MDE.
Suicidal Risk in Bipolar Disorder
Increased Risk Factors: Bipolar 2 disorder, psychiatric hospitalization, and substance use.
Treatment Approaches
Acute Phase Treatment
Goals: Rapid control of mood symptoms and agitation, restore sleep, and reduce the risk of harm to oneself or others.
Continuation Phase Treatment
Goals: Prevent relapse and minimize adverse effects. Support adherence to treatments.
Maintenance Phase Treatment
Goals: Achieve mood stability for at least three months and improve functioning. Use the lowest effective number of medications.
Long-Term Treatment Strategies
Medications
Mood Stabilizers:
Lithium: Gold standard for mood stabilization.
Lamotrigine: Effective for maintenance treatment.
Carbamazepine & Divalproex: Commonly used as mood stabilizers.
Second-Generation Antipsychotics (SGAs):
Used in acute mania, bipolar depression, and for maintenance therapy.
Antidepressants:
Bupropion and SSRIs should be used with a mood stabilizer; not recommended as monotherapy due to the potential for inducing mania.
Non-Pharmacological Options
Lifestyle Management: Regular sleep, exercise, and nutrition.
Psychoeducation: Educating patients about their condition.
ECT: Recommended only for severe or refractory cases.
Neuromodulation: Bright light therapy may be beneficial for bipolar depression.
Lithium Specifics
FDA Approval: Approved for acute mania and maintenance treatment.
Characteristics: Considered the gold standard mood stabilizer; reduces suicide risk.
Narrow Therapeutic Index: Wrong doses can cause toxic levels.
Dosage Guidelines for Lithium
Starting Dose: 600-800 mg/day.
Maintenance Dose: 900-1200 mg/day.
Target Serum Levels:
Acute Mania: 0.8-1.2 mEq/L
Maintenance: 0.6-1.0 mEq/L
Steady State Timeframe: 5 days where the first level is recorded; lithium levels must be checked carefully.
Lithium Administration Considerations
Administration Instructions: Take with food if gastrointestinal upset occurs. Maintain hydration and consistent salt intake.
Monitoring Requirements: Regular monitoring of BMP, TSH, CBC, weight, pregnancy test, and ECG. Check lithium levels regularly.
Contraindications of Lithium
Warnings: #
Dehydration, use of diuretics, sodium depletion, renal or cardiovascular disease, pregnancy (particularly avoid in the first trimester due to cardiac malformations).
Toxicity Signs:
Levels $ ext{>}$ 1.5-2.0 mEq/L can signal gastrointestinal issues, mild ataxia, and tremors. Levels $ ext{>}$ 2.5 mEq/L may lead to severe complications including coma and cardiovascular collapse.
Drug-Drug Interactions with Lithium
Drugs Increasing Lithium Levels:
NSAIDs (except aspirin and sulindac), ACE inhibitors, ARBs, and diuretics (thiazides).
Drugs Decreasing Lithium Levels:
Caffeine and high sodium intake.
Serotonergic Drugs: Risk of serotonin syndrome with SSRIs, SNRIs, and Linezolid.
Divalproex Sodium
Indication: Monotherapy or with antipsychotics for acute manic and mixed episodes.
Mechanism: Increases GABA and decreases neuronal excitability.
Loading Strategy: 20-30 mg/kg immediate-release or 25 mg/kg extended-release.
Initial Titration Plan: Start with 500-750 mg at bedtime on day 1, increase by 500 mg daily, max dosage 60 mg/kg/day.
Serum Concentration for Divalproex
Target Range: 50-125 mcg/mL; wide therapeutic range allows flexibility, even above 126 mcg/mL being acceptable in clinical context.
Contraindications of Divalproex
High-Risk Groups: Hepatic disease, pregnancy, mitochondrial disorders.
Precautions: Hepatotoxicity, pancreatitis, hyperammonemic encephalopathy, and dose-related thrombocytopenia.
Divalproex Adverse Effects
Potential Side Effects: Neurologic issues (dizziness), gastrointestinal issues (diarrhea, nausea), hepatotoxicity, alopecia, rash, and thrombocytopenia.
Hemodialysis Consideration: Hemodialysis may be an option in severe cases of toxicity.
Monitoring Divalproex Levels
Timing for Checking Levels: 3-4 days after initiation or when a stable dose is achieved.
Counseling Points for Divalproex
Usage Guidance: Take with food to reduce gastrointestinal upset. Avoid in pregnancy unless using high doses of folic acid to reduce neural tube defect risk.